Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
      • XR-19
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Analyst coverage

Thomas Nilsson
Thomas Nilsson

Read more

Oasmia Pharmaceutical AB – Analysguiden 211206
Swedish December 6, 2021
Dr Joseph Hedden
Dr Joseph Hedden
Oasmia Pharmaceutical AB – Q3 results update
English November 18, 2021
Oasmia Pharmaceutical AB – Q2 results update
English August 19, 2021
Oasmia Pharmaceutical AB – Cantrixil Phase I data published in peer-reviewed journal
English June 30, 2021
Oasmia Pharmaceutical AB – Inceptua to now commercialise Apealea® in the Nordics
English June 28, 2021
Oasmia Pharmaceutical AB – Q1 results update
May 27, 2021
Oasmia Pharmaceutical AB – In-licenses clinical-stage ovarian cancer drug
1 March 2021
Oasmia Pharmaceutical AB – Phase Ib of docetaxel micellar in prostate cancer authorised
April 21, 2021
Klas Palin
Klas Palin

Read more

Färdigstädat
October 21, 2021
Oasmia – ny partner i öst
Svenska September, 2021
Q2 Update
English August 20, 2021
Q1 Update
English May 28, 2021
Dr Sean Conway & Dr Jonas Peciulis
Dr Sean Conway & Dr Jonas Peciulis

Read more

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Investors
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com